5-(2,3-dihydro-1-benzofuran-5-yl)-1,3,4-oxadiazole-2-thiol | 1005200-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 英文名称: 5-(2,3-dihydro-1-benzofuran-5-yl)-1,3,4-oxadiazole-2-thiol
• 英文别名: 5-(2,3-dihydrobenzofuran-5-yl)-[1,3,4]oxadiazole-2-thiol；5-(2,3-dihydro-1-benzofuran-5-yl)-3H-1,3,4-oxadiazole-2-thione
• CAS: 1005200-16-7
• 化学式: C₁₀H₈N₂O₂S
• 分子量: 220.252
• InChiKey: ICQYKJPVCLQHCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(2,3-dihydro-1-benzofuran-5-yl)-1,3,4-oxadiazole-2-thiol 、 间氟氯苄 在 sodium hydroxide 作用下， 以 水 为溶剂， 以74%的产率得到2-(2,3-dihydro-1-benzofuran-5-yl)-5-[(3-fluorobenzyl)sulfanyl]-1,3,4-oxadiazole
  参考文献：
  名称：

  GSK-3BETAINHIBITOR

  摘要：

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。

  公开号：

  US20100069381A1
• 作为产物：
  描述：

  2,3-二氢-5-苯并呋喃羧酸甲酯 在 一水合肼 、 potassium hydroxide 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 15.5h， 生成 5-(2,3-dihydro-1-benzofuran-5-yl)-1,3,4-oxadiazole-2-thiol
  参考文献：
  名称：

  [EN] NOVEL OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE
  [FR] NOUVEAUX DÉRIVÉS D'OXADIAZOLYL-DIAZABICYCLONONANE ET LEUR UTILISATION MÉDICALE

  摘要：

  这项发明涉及新型氧代噻二唑基-双氮杂环庚烷衍生物及其在制备药物组合物中的应用。本发明的化合物被发现是胆碱能受体的胆碱能配体，并且是单胺受体和转运体的调节剂。由于它们的药理特性，本发明的化合物可能对治疗与中枢神经系统（CNS）的胆碱能系统、外周神经系统（PNS）、平滑肌收缩、内分泌疾病或紊乱、神经退行性疾病、炎症、疼痛以及由滥用化学物质终止引起的戒断症状等各种疾病或紊乱有用。

  公开号：

  WO2009150138A1

文献信息

• NOVEL OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE
  申请人：Peters Dan

  公开号：US20110112078A1

  公开（公告）日：2011-05-12

  This invention relates to novel oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholin receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及新型的氧代噻唑基-二氮杂双环壬烷衍生物及其在制备药物组合物方面的应用。本发明的化合物被发现是尼古丁酸乙酰胆碱受体的胆碱能配体和单胺类受体和转运体的调节剂。由于其药理学特性，本发明的化合物可能有助于治疗与中枢神经系统（CNS）的胆碱能系统、周围神经系统（PNS）、平滑肌收缩相关的疾病或疾病、内分泌疾病或疾病、神经退行性疾病或疾病、炎症相关的疾病或疾病、疼痛和因化学物质滥用终止而引起的戒断症状等多种疾病或疾病的治疗。
• GSK-3β inhibitor
  申请人：Itoh Fumio

  公开号：US08492378B2

  公开（公告）日：2013-07-23

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁唑烷化合物或其盐或前药的GSK-3β抑制剂，该抑制剂可用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种包含式（I）所表示的化合物的GSK-3β抑制剂：其中每个符号如规范中所定义，或其盐或前药。
• Design, synthesis and structure–activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β
  作者：Morihisa Saitoh、Jun Kunitomo、Eiji Kimura、Yoji Hayase、Hiromi Kobayashi、Noriko Uchiyama、Tomohiro Kawamoto、Toshimasa Tanaka、Clifford D. Mol、Douglas R. Dougan、Garret S. Textor、Gyorgy P. Snell、Fumio Itoh

  DOI：10.1016/j.bmc.2009.01.019

  日期：2009.3

  Glycogen synthase kinase-3beta (GSK-3beta) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3beta inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3beta inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3beta.
• US8492378B2
  申请人：——

  公开号：US8492378B2

  公开（公告）日：2013-07-23
• GSK-3BETAINHIBITOR
  申请人：Itoh Fumio

  公开号：US20100069381A1

  公开（公告）日：2010-03-18

  For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.

  为了提供一种含有噁二唑化合物或其盐或其前药的GSK-3β抑制剂，用作GSK-3β相关病理或疾病的预防或治疗剂，本发明提供了一种含有由以下式（I）表示的化合物的GSK-3β抑制剂： 其中每个符号如规范中定义，或其盐或其前药。